BridgeBio Pharma (NASDAQ: BBIO) is a biotech on the verge of a breakout. The company focuses on rare genetic diseases. It has only two approved therapies right now: Attruby and Nulibry. Attruby is the company's main earner right now. The drug treats transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a rare type of heart disease. The drug was responsible for 71% of the company's revenue in the third quarter. Nulibry is designed to treat infants with molybdenum cofactor deficiency, a rare disease that can lead to seizures and brain abnormalities.
CryptoAlerta — análise de criptomoedas e mercado em tempo real